NE
NERV.US Minerva Neurosciences Inc
- Market cap
- USD 115M
- P/E
- -
- P/B
- 2.68x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NERV.US undervalued?
Graham numberThe Graham number of Minerva Neurosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Minerva Neurosciences Inc fundamental analysis
No fundamental analysis for Minerva Neurosciences Inc yet.
Minerva Neurosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Full company profileMinerva Neurosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Minerva Neurosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 41.2M | 41.2M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -16.5K | -11.1K | -17.5K | -162K | 41.2M | -102K | -8.51K | -31.0K | -22.5K | -5.44K | - |
| Operating Income | -30.2M | -41.2M | -51.7M | -75.9M | 1.85M | -45.4M | -25.2M | -23.1M | -21.8M | -15.1M | -49.0M |
| EBITDA | -30.0M | -40.3M | -50.0M | -74.3M | 2.12M | -45.3M | -24.7M | -21.7M | 6.02M | -293M | -9.59M |
| Net Income | -31.0M | -31.5M | -50.2M | -72.2M | 1.94M | -49.9M | -32.1M | -30.0M | 1.44M | -293M | -9.59M |
| EPS | -7.88 | -6.65 | -10 | -15 | 0.38 | -9.35 | -6.01 | -4.61 | 0.19 | -35 | -0.13 |
| Balance Sheet | |||||||||||
| Total Assets | 133M | 184M | 139M | 77.5M | 57.6M | 77.1M | 55.1M | 56.9M | 37.1M | 98.0M | 98.3M |
| Total Liabilities | 27.0M | 52.1M | 48.9M | 49.7M | 4.96M | 69.1M | 75.1M | 85.4M | 62.8M | 239M | 184M |
| Shareholders' Equity | 106M | 132M | 90.3M | 27.8M | 52.7M | 7.98M | -20.0M | -28.5M | -25.7M | -141M | -97.5M |
| Cash & Short-term Investments | 83.0M | 128M | 88.0M | 45.9M | 25.4M | 60.8M | 36.1M | 40.9M | 21.4M | 82.3M | 76.9M |
| Total Debt | 8.69M | 3.96M | - | 284K | 111K | - | 73.7M | 82.0M | 60.0M | 65.0M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -25.7M | 3.09M | -41.9M | -43.4M | -33.8M | -24.6M | -24.6M | -14.8M | -19.6M | -13.5M | -35.9M |
| Capital Expenditure | 52.4K | 52.4K | 0.00 | 3.00 | 16.3K | 16.3K | 16.3K | 2.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -25.7M | 3.04M | -41.9M | -43.4M | -33.8M | -24.6M | -24.7M | -14.8M | -19.6M | -13.5M | -35.9M |
| Ratios | |||||||||||
| ROE | -29.3% | -24.0% | -55.6% | -259.8% | 3.7% | -625.7% | - | - | - | - | - |
| ROA | -23.4% | -17.2% | -36.1% | -93.1% | 3.4% | -64.7% | -58.3% | -52.7% | 3.9% | -299.5% | -9.8% |
| Net Profit Margin | - | - | - | -175.3% | 4.7% | - | - | - | - | - | - |
| Debt to Equity | 0.08x | 0.03x | - | 0.01x | 0.00x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Minerva Neurosciences Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | USD 10.5M | 2.21 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:8 on Jun 21, 2022.
Who owns Minerva Neurosciences Inc
- Insiders 3.43%
- Institutions 90.06%
- Public & others 6.51%
- Shares outstanding 49.8M
- Free float 36.4M
Top funds holding NERV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.41M | 2.82% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 808K | 1.62% | 0.00% | Oct 2026 |
| Federated Hermes Kaufmann Small Cap A | 502K | 1.01% | 0.00% | Sep 2026 |
| Federated Hermes Kaufmann R | 484K | 0.97% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 373K | 0.75% | +0.84% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 223K | 0.45% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 209K | 0.42% | +6.65% | Sep 2026 |
| Fidelity Extended Market Index | 201K | 0.40% | -12.35% | Sep 2026 |
| iShares Micro-Cap ETF | 110K | 0.22% | 0.00% | Oct 2026 |
| Bridge Builder Small Cap Fund | 97.5K | 0.20% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 93.2K | 0.19% | +12.82% | Sep 2026 |
| iShares Russell 2000 Value ETF | 92.7K | 0.19% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 84.7K | 0.17% | -0.05% | Sep 2026 |
| Fidelity Series Total Market Index | 70.8K | 0.14% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 63.6K | 0.13% | 0.00% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 45.5K | 0.09% | 0.00% | Sep 2026 |
Top institutions holding NERV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Federated Hermes Inc | 4.67M | 9.37% | -8.66% | Jun 2026 |
| Jupiter Topco LLC | 4.39M | 8.80% | 0.00% | Jun 2026 |
| Vivo Capital, LLC | 4.32M | 8.67% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 4.26M | 8.54% | -0.04% | Jun 2026 |
| Logos Global Management LP | 3.29M | 6.60% | +2.29% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 2.37M | 4.75% | 0.00% | Jun 2026 |
| BlackRock Inc | 2.24M | 4.50% | +258.57% | Jun 2026 |
| Ally Bridge Group (NY) LLC | 2.18M | 4.37% | +31.43% | Jun 2026 |
| Foresite Capital Management VI LLC | 1.99M | 3.98% | -0.05% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.89M | 3.80% | +2.55% | Jun 2026 |
| Spruce Street Capital LP | 1.66M | 3.32% | 0.00% | Jun 2026 |
| Trails Edge Capital Partners, LP | 1.42M | 2.85% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.42M | 2.85% | 0.00% | Jun 2026 |
| Seven Fleet Capital Management LP | 1.00M | 2.01% | +303.01% | Jun 2026 |
| Geode Capital Management, LLC | 974K | 1.95% | +187.61% | Jun 2026 |
| DV EQUITIES, LLC | 754K | 1.51% | 0.00% | Jun 2026 |
| Longwood Capital Partners LLC | 710K | 1.42% | 0.00% | Jun 2026 |
| Millennium Management LLC | 534K | 1.07% | -24.66% | Jun 2026 |
| State Street Corp | 425K | 0.85% | +654.08% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 303K | 0.61% | +14.60% | Jun 2026 |
Minerva Neurosciences Inc company profile
- Company name
- Minerva Neurosciences Inc
- Ticker
- NERV.US
- Exchange
- USA Stocks
- Listed since
- Jul 1, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 7
- Fiscal year end
- December
- Address
- 1500 District Avenue, Burlington, MA, United States, 01803
- Phone
- 617 600 7373
- Website
- minervaneurosciences.com
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Minerva Neurosciences Inc management
7- Dr. Remy Luthringer Ph.D.Executive Chairman, CEO & Member of Scientific Advisory Board · born 1961
- Mr. Frederick W. Ahlholm CPASenior VP, CFO & Secretary · born 1966
- Mr. Joseph ReillySenior VP & COO · born 1975
- Mr. Anthony AliquoChief Accounting Officer & Principal Accounting Officer · born 1987
- Mr. William B. BoniVice President of Investor Relations & Corporate Communications · born 1952
- Mr. James O'ConnorChief Business Officer & General Counsel · born 1974
- Prof. Michael Davidson M.D.Member of Scientific Advisory Board & Chief Medical Officer · born 1950